Status:
COMPLETED
Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Relapsing Forms of Multiple Sclerosis
Eligibility:
All Genders
18-100 years
Brief Summary
This is an observational cross-sectional study of Ocrelizumab or Ofatumumab administrations for Relapsing forms of Multiple Sclerosis (RMS) in selected sites in the US, the UK and Australia.
Detailed Description
Patients with RMS receiving Ocrelizumab or Ofatumumab will be recruited to measure the time spend for Healthcare Providers (HCP) (neurologist, nurse and hospital pharmacist) on preparing, administerin...
Eligibility Criteria
Inclusion
- Adult patients of 18 or more years of age.
- Patients with confirmed diagnosis of RMS (CIS, RRMS or aSPMS) following 2017 McDonnald criteria.
- Patients currently prescribed with Ocrelizumab or Ofatumumab to treat MS according to the Summary of Product Characteristics (SmPC). The decision must be based on patient disease and taken before the decision of inviting the patient to participate in this study.
- Patients literate in English.
- Patients must provide informed consent to participate in the study.
Exclusion
- Patients currently participating in any other RMS clinical trial.
Key Trial Info
Start Date :
May 11 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 21 2021
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT04676555
Start Date
May 11 2021
End Date
October 21 2021
Last Update
October 24 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Lutherville, Maryland, United States, 21093
2
Novartis Investigative Site
Parkville, Victoria, Australia, 3050